No headlines found.
Immunome Appoints Sandra M. Swain to Board of Directors
Business Wire (Thu, 25-Apr 8:26 AM ET)
Business Wire (Fri, 5-Apr 8:00 AM ET)
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
Business Wire (Thu, 28-Mar 4:02 PM ET)
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
Globe Newswire (Tue, 26-Mar 8:00 AM ET)
Business Wire (Tue, 26-Mar 8:00 AM ET)
Business Wire (Mon, 18-Mar 5:44 AM ET)
Immunome to Participate in the Leerink Partners Global Biopharma Conference
Business Wire (Thu, 7-Mar 8:00 AM ET)
Globe Newswire (Mon, 4-Mar 7:00 AM ET)
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
Business Wire (Fri, 1-Mar 8:00 AM ET)
Business Wire (Tue, 20-Feb 8:15 AM ET)
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
Immunome trades on the NASDAQ stock market under the symbol IMNM.
As of April 25, 2024, IMNM stock price climbed to $14.44 with 136,791 million shares trading.
IMNM has a beta of 1.32, meaning it tends to be more sensitive to market movements. IMNM has a correlation of 0.03 to the broad based SPY ETF.
IMNM has a market cap of $856.91 million. This is considered a Small Cap stock.
Last quarter Immunome reported $4 million in Revenue and -$.15 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.13.
In the last 3 years, IMNM stock traded as high as $32.45 and as low as $2.09.
The top ETF exchange traded funds that IMNM belongs to (by Net Assets): VTI, VXF, DWAS, PTH, IWC.
IMNM has outperformed the market in the last year with a return of +172.5%, while the SPY ETF gained +22.7%. However, in the most recent history, IMNM shares have underperformed the stock market with its stock returning -5.7% in the last 3 month period and -29.0% for the last 2 week period, while SPY has returned +3.2% and -2.9%, respectively.
IMNM support price is $13.52 and resistance is $15.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMNM stock will trade within this expected range on the day.